Business Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Speciality Dialogues
    • Education Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Business Medical Dialogues
    • News
        • Financial Results
        • Hospitals & Diagnostics
        • IT / Health Venture
        • Implants / Devices
        • Insurance
        • Key Movement
        • Pharmaceuticals
        • Policy
        • Technology
        • pharma-news
    • blog
    LoginRegister
    Business Medical Dialogues
    LoginRegister
    • Home
    • News
      • Financial Results
      • Hospitals & Diagnostics
      • IT / Health Venture
      • Implants / Devices
      • Insurance
      • Key Movement
      • Pharmaceuticals
      • Policy
      • Technology
      • pharma-news
    • blog
    • Home
    • Latest News
    • Novo Nordisk defends...

    Novo Nordisk defends US diabetes drug pricing

    Written by supriya kashyap kashyap Published On 2016-11-06T11:09:03+05:30  |  Updated On 6 Nov 2016 11:09 AM IST
    Novo Nordisk defends US diabetes drug pricing

    Copenhagen : Danish diabetes drug maker Novo Nordisk defended its pricing of diabetes drugs after facing allegations of pricing collusion by U.S. senators.


    "In order to get on the (product lists), which receive subsidies by the different insurance companies, we need to offer rebates," Mike Rulis, senior vice president of corporate communications told Reuters.


    "Those rebates have increased over the years, as well as list prices."


    The world's largest insulin maker gets around half its revenue in the United States, but prices have been squeezed by pharmacy benefit managers (PBMs) who administer drug benefits and negotiate rebates for employers and health plans.


    U.S. Senator Bernie Sanders and Representative Elijah Cummings called on antitrust regulators on Thursday to investigate whether insulin and diabetes drugs makers such as Sanofi SA, Eli Lilly and Co and Novo Nordisk have colluded to set drug prices on the U.S. market.


    Last year Novo Nordisk offered an average rebate of 55 percent on its products in the United States, Rulis told Reuters, but could not elaborate further due to trade confidentiality.


    Some U.S. consumers have experienced price increases, while others have not, he said.


    Novo Nordisk shares were down 3.0 percent at 1047 GMT on the Copenhagen main index.

    diabetesdiabetes drugEli LillyElijah CummingsMike RulisNovo NordiskPBMpharmacy benefit managerSanofi

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    supriya kashyap kashyap
    supriya kashyap kashyap
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      Popular Stories

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 13 Oct 2022 5:14 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok